Sponsors of six new drugs are set to learn this week whether their products are on track for possible EU-wide approval, including Janssen for its CAR-T therapy for multiple myeloma ciltacabtagene autoleucel (cilta-cel) and AstraZeneca for its COVID-19 preventive treatment Evusheld (tixagevimab/cilgavimab).
Cilta-cel was authorized as Carvykti in the US three weeks ago, while Evusheld was approved for emergency use in the...